ReviewDrugs - real world outcomes2021
Current Status, Challenges, and Future Perspectives of Real-World Data and Real-World Evidence in Japan.
Review in Drugs - real world outcomes, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed.
- A scoping review of real-world data sources for retrospective oncology analysis in Japan.ESMO real world data and digital oncology · 2026Review
- COVID-19 as a Potential Trigger for Tuberculosis: Insights From a Large-Scale Japanese Insurance Database Analysis.Journal of general and family medicine · 2026Article
- Japan's health system toward 2040: structural challenges and a renewed social contract.The Lancet regional health. Western Pacific · 2026Review
- Validation of Recorded Diagnoses of Acute Kidney Injury Among Surgical Patients in the Japanese Diagnosis Procedure Combination Database.Journal of epidemiology · 2026Article
- Real-World Evidence of Treatment Outcomes in Small Cell Lung Cancer: A Bayesian Mixed Effects and Competitive Risk Approach.JMIR cancer · 2026Article
- Association between Early Diagnosis, Surgery and Prognosis in Patients with High-Grade Glioma: Retrospective Analysis of a Real-World Healthcare Claims Database in Japan.Neurologia medico-chirurgica · 2026Article
- Epigenetic plasticity and chemoresistance in cancer: mechanisms, biomarkers, and translational opportunities for real-world evidence.Frontiers in cell and developmental biology · 2026Review
- Effect of Early-Onset Dementia on Job Loss in Japan: A Matched Cohort Database Study Using Health Insurance Claims Data.Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society · 2026Article
- Assessment of the Representation of Civil Servants as the General Population in Terms of Health Checkup Data.Cureus · 2025Article
- Children Comorbidity Score, a Simple Predictor for In-hospital Mortality: A Nationwide Inpatient Database Study in Japan.JMA journal · 2025Article
- Usefulness and caveats of real-world data for research on hypertension and its association with cardiovascular or renal disease in Japan.Hypertension research : official journal of the Japanese Society of Hypertension · 2024Review
- Annual trends in atypical haemolytic uremic syndrome management in Japan and factors influencing early diagnosis and treatment: a retrospective study.Scientific reports · 2024Article
- Risk of Urogenital Bacterial Infection with Sodium-Glucose Cotransporter-2 Inhibitors: A Retrospective Cohort Study Using a Claims Database.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2024Article
- Accessible Ecosystem for Clinical Research (Federated Learning for Everyone): Development and Usability Study.JMIR formative research · 2024Article
- Long-term efficacies of selective vasodilators in pulmonary arterial hypertension: a comprehensive comparison using a spontaneous reporting database.Naunyn-Schmiedeberg's archives of pharmacology · 2024Article
- Real-world evidence of systemic treatment practices for biliary tract cancer in Japan: Results of a database study.Journal of hepato-biliary-pancreatic sciences · 2024Article
- Integrated Real-World Data Warehouses Across 7 Evolving Asian Health Care Systems: Scoping Review.Journal of medical Internet research · 2024Article
- Early-onset dementia and risk of hip fracture and major osteoporotic fractures.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Expert survey on real-world data utilization and real-world evidence generation for regulatory decision-making in drug lifecycle in Korea.Clinical and translational science · 2024Article
- The emerging role of real-world data in oncology care in Japan.ESMO real world data and digital oncology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this article is to help develop a common understanding of the current status, challenges, and future perspectives of real-world data (RWD) and real-world evidence (RWE) in Japan. RWD and RWE are very widely used terms, but standardized definitions are lacking. Given broad and growing applications of RWD/RWE from the perspective of clinical development and medical affairs, the PhRMA Japan Medical Affairs Committee Working Group 1 have proposed the following definitions: "RWD are the data relating to patient health status and/or the delivery of health care routinely collected from a variety of sources" and "RWE is the evidence derived from analysis of RWD." The key challenges for RWD and RWE in Japan include restricted access and linkage of RWD, as well as a lack of universally accepted methodological approaches, which reduces the potential for patient and healthcare benefits. These challenges for RWD/RWE are by no means unique to Japan and similar challenges exist for countries in Europe and the USA. The quality of data and analysis, study design, and the transparency of reporting should be discussed more to ensure credibility and acceptance by decision-makers as the demand for RWD and RWE increases. The future developments around Japan's RWD and RWE are expected to include improved RWD access, data linkage, and increased acceptance by decision-makers, all supported by innovative technology. Improvements in RWD access and database linkage will enable both public and private sectors to assemble more comprehensive health information in Japan.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.